KROS vs BEAM vs IMVT vs EDIT vs REGN

For growth investors, Keros Therapeutics, Inc.

(KROS) is the stronger pick with 67. 7% revenue growth year-over-year, versus -100. 0% for Editas Medicine, Inc. (EDIT). Keros Therapeutics, Inc. (KROS) offers the better valuation at 5. 2x trailing P/E, making it the more compelling value choice. Analysts rate Keros Therapeutics, Inc. (KROS) a "Buy" — based on 16 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Keros Therapeutics, Inc.

(KROS) is the cheapest at 5. 2x versus Regeneron Pharmaceuticals, Inc. at 17. 2x.

Over the past 5 years, Immunovant, Inc.

(IMVT) delivered a total return of +84. 4%, compared to -90. 1% for Editas Medicine, Inc. (EDIT). Over 10 years, the gap is even starker: IMVT returned +190. 9% versus EDIT's -89. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Regeneron Pharmaceuticals, Inc.

(REGN) is the lower-risk stock at 0. 77β versus Editas Medicine, Inc. 's 2. 45β — meaning EDIT is approximately 219% more volatile than REGN relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 66% for Editas Medicine, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Keros Therapeutics, Inc.

(KROS) is pulling ahead at 67. 7% versus -100. 0% for Editas Medicine, Inc. (EDIT). On earnings-per-share growth, the picture is similar: Keros Therapeutics, Inc. grew EPS 146. 0% year-over-year, compared to -45. 2% for Immunovant, Inc.. Over a 3-year CAGR, BEAM leads at 31. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Keros Therapeutics, Inc.

(KROS) is the more profitable company, earning 35. 7% net margin versus -57. 2% for Beam Therapeutics Inc. — meaning it keeps 35. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KROS leads at 28. 9% versus -274. 6% for BEAM. At the gross margin level — before operating expenses — KROS leads at 99. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for KROS: 750.

0% to $102. 60.

In this comparison, REGN (0.

5% yield) pays a dividend. KROS, BEAM, IMVT, EDIT do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Regeneron Pharmaceuticals, Inc.

(REGN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 77)). Editas Medicine, Inc. (EDIT) carries a higher beta of 2. 45 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (REGN: +91. 6%, EDIT: -89. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: KROS is a small-cap high-growth stock; BEAM is a small-cap high-growth stock; IMVT is a small-cap quality compounder stock; EDIT is a small-cap quality compounder stock; REGN is a mid-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.